Evidence map›Paper›PMID 37711802›Full record

ArticleQuantitative imaging in medicine and surgery2023

The baseline metabolism parameters of

Xia Lu, Ang Wei, Guanyun Wang, Junye Du, Lijuan Feng, Wenxin Ou, Tianyou Wang, Wei Wang, Jixia Li, Mingyu Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Application of pretreatmentAnnals of hematology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xia Lu *Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ang Wei *Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Guanyun Wang *Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Junye DuHematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Lijuan FengNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wenxin OuHematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Tianyou WangHematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Wei WangNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jixia LiDepartment of Laboratory Medicine, School of Medicine, Foshan University, Foshan, China.
Mingyu ZhangNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Rui ZhangHematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jigang YangNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Langerhans cell histiocytosis (LCH) is a rare myeloid precursor cell inflammatory neoplasia, which agonizes, maims, and even kills patients. Although clinical outcomes have steadily improved over the past decades, the progression/relapse rate of LCH remains high. The purpose of this study was to evaluate the prognostic value of the pre-treatment metabolism parameters of baseline Methods: This cross-sectional study retrospectively and consecutively included 37 children (24 males and 13 females; median age, 5.1 years; range, 2.4-7.8 years) with pre-treatment Results: During follow-up, 11 (29.7%) patients had disease progression/relapse. Univariate analysis revealed that the risk organ involvement, the treatment response at the 5 Conclusions: The baseline metabolism parameters of

Indexed as

18F-fluorodeoxyglucose (18F‑FDG)childrenLangerhans cell histiocytosis (LCH)prognosis

Identifiers

PMID37711802
PMCPMC10498231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.